ArticleEuropean stroke journal2026
Efficacy and safety of early tirofiban administration after intravenous thrombolysis in patients with acute ischaemic stroke: the multicentre, randomised, double-blind, placebo-controlled RESCUE BT3 trial protocol.
Article in European stroke journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundIntravenous thrombolysis (IVT) is the standard first-line treatment for patients with acute ischaemic stroke (AIS). However, a significant number of these patients fail to achieve favourable functional outcomes. Early administration of tirofiban may improve functional outcomes in patients who fail to respond to IVT. STUDY
designThe RESCUE BT3 trial is a multicentre, randomised, double-blind, placebo-controlled trial. A total of 1314 AIS patients without large or medium vessel occlusion and with persistent disability after IVT will be randomised in a 1:1 ratio to receive intravenous tirofiban or placebo within 2-24 h after completion of IVT. STUDY ENDPOINTS: The primary efficacy endpoint is the proportion of patients achieving an excellent functional outcome (mRS score 0-1) at 90 days. Secondary endpoints include functional independence (mRS 0-2), ordinal mRS shift, NIHSS change and quality-of-life measures. Safety outcomes include sICH within 48 h and all-cause mortality at 90 days. SUMMARY: This trial aims to determine whether early tirofiban administration after IVT improves functional outcomes without increasing haemorrhagic risk in AIS patients without large or medium vessel occlusion. The results will provide high-quality evidence for adjunctive antiplatelet therapy in this population.
trial registrationchiCTR2400080653 (www.chictr.org.cn).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.